Market Research Logo

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
  • The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview
Therapeutics Development
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Amgen Inc.
Antisense Therapeutics Limited
Astellas Pharma Inc.
AstraZeneca Plc
Axelar AB
Boehringer Ingelheim GmbH
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
Immunomedics, Inc.
Insmed Incorporated
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Novartis AG
PharmAbcine, Inc.
Prometheon Pharma, LLC
ProteoThera, Inc.
Silver Creek Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
TyrNovo Ltd.
XL-protein GmbH
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles
1R-15-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1R-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1R-3s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
1R-E1-E1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXL-1717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-3463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-893923 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-707 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalotuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganitumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hex-hR1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
istiratumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenaldekar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linsitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize Insulin Like Growth Factor 1 Receptor for Hormone Replacement Therapy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Insulin Like Growth Factor 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize IGF-1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RU-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize IGF-1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IGF1R for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vesiculin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XGFR-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XGFR-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases
Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting
Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy
May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer
Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
Mar 17, 2015: Study suggests precision medicine for adrenal cancer
Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium
Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer
Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting
Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer
Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer
Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease
Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by Antisense Therapeutics Limited, H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Axelar AB, H2 2016
Pipeline by Boehringer Ingelheim GmbH, H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by Genmab A/S, H2 2016
Pipeline by Immunomedics, Inc., H2 2016
Pipeline by Insmed Incorporated, H2 2016
Pipeline by Merck & Co., Inc., H2 2016
Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by PharmAbcine, Inc., H2 2016
Pipeline by Prometheon Pharma, LLC, H2 2016
Pipeline by ProteoThera, Inc., H2 2016
Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016
Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Pipeline by TyrNovo Ltd., H2 2016
Pipeline by XL-protein GmbH, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Dormant Projects (Contd..3), H2 2016
Dormant Projects (Contd..4), H2 2016
Dormant Projects (Contd..5), H2 2016
Dormant Projects (Contd..6), H2 2016
Discontinued Products, H2 2016
Discontinued Products (Contd..1), H2 2016
Discontinued Products (Contd..2), H2 2016
Discontinued Products (Contd..3), H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report